Tema Oncology ETF CANC

Morningstar Medalist Rating

Morningstar’s Analysis CANC

Will CANC outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Tema Oncology ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CANC

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings45.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Genmab AS ADR

5.9512M
Healthcare

Eli Lilly and Co

5.6812M
Healthcare

Revolution Medicines Inc Ordinary Shares

5.2711M
Healthcare

Merck & Co Inc

5.0210M
Healthcare

BeOne Medicines Ltd ADR

4.379M
Healthcare

Novartis AG Registered Shares

4.339M
Healthcare

Cogent Biosciences Inc

4.229M
Healthcare

AbbVie Inc

3.958M
Healthcare

Exelixis Inc

3.718M
Healthcare

CG Oncology Inc

3.357M
Healthcare

Sponsor Center